Injectable Drug Delivery Devices Market to Reach $1.06 Trillion by 2032, Driven by Biologics Boom and Smart Device Innovation
核心洞察
The global injectable drug delivery devices market is projected to grow from $570.77 billion in 2024 to $1,056.10 billion by 2032, at a CAGR of 8.10%.
Rising prevalence of chronic diseases—including 537.5 million adults with diabetes (搜索) globally—and expanding biologics pipelines are key growth drivers.
Recent regulatory milestones include EMA clearance for Insulet (搜索)'s Omnipod 5 wearable injector and FDA approval of Xolair prefilled syringes for self-injection.
The global injectable drug delivery devices market is on track to surpass the trillion-dollar mark, with DelveInsight projecting growth from USD 570.77 billion in 2024 to USD 1,056.10 billion by 2032, reflecting a compound annual growth rate (CAGR) of 8.10% during the 2025–2032 forecast period. This sustained expansion underscores the pharmaceutical industry's accelerating shift toward advanced parenteral delivery platforms capable of handling increasingly complex biologic therapies.
Chronic Disease Burden Fuels Demand
The market's growth trajectory is closely tied to the rising global prevalence of chronic diseases requiring long-term injectable therapies. According to DelveInsight, approximately 537.5 million adults aged 20–79 were living with diabetes (搜索) globally—roughly one in ten individuals—a number projected to reach 643 million by 2030 and 783.5 million by 2045. In the United States alone, approximately 38.4 million people of all ages, or roughly 11.6% of the population, are affected by diabetes, with prevalence reaching 29.2% among individuals aged 65 and older.
Beyond diabetes (搜索), DelveInsight reports that approximately 13.5 million people worldwide are affected by rheumatoid arthritis (搜索), while multiple sclerosis (搜索) impacts over 2 million individuals globally. These growing patient populations, combined with the expanding biologics pipeline and increasing preference for patient-centric self-administration, are creating sustained and accelerating demand for injectable drug delivery devices worldwide.
Regulatory Milestones Signal Market Momentum
Recent regulatory actions highlight the sector's dynamism. The European Medicines Agency (EMA) granted clearance for Insulet (搜索)'s Omnipod 5 automated wearable injector, marking what DelveInsight describes as "a significant regulatory milestone in patient-friendly self-administration technology." Concurrently, the U.S. FDA approved a supplemental Biologics License Application for Xolair (omalizumab) prefilled syringes, enabling self-injection across all approved U.S. indications.
On the product innovation front, Becton Dickinson (BD (搜索)) launched the NOVA prefillable syringe platform designed specifically for advanced biologics, while West Pharmaceutical Services unveiled smart connected drug delivery platforms aimed at supporting patient adherence.
North America Dominates, Asia Pacific Accelerates
North America remains the dominant force in the injectable drug delivery devices market, accounting for approximately 43% of the total market share in 2024. DelveInsight attributes this leadership to the rising prevalence of chronic diseases, strong healthcare infrastructure, favorable reimbursement policies, and high adoption of advanced self-administered therapies.
Meanwhile, a separate analysis from MarketsandMarkets covering the broader pharmaceutical drug delivery market—projected to reach USD 2,922.82 billion by 2031 at a CAGR of 6.3%—identifies the Asia Pacific region as the fastest-growing market. Growth in this region is driven by a rapidly expanding patient population, increasing prevalence of chronic diseases, and rising demand for advanced therapeutics in countries such as China, India, and Japan. Improving healthcare infrastructure, increasing healthcare spending, and supportive government initiatives are further boosting market growth, with the region emerging as a key hub for pharmaceutical manufacturing and contract development.
Innovation Driving Competitive Dynamics
The competitive landscape of the injectable drug delivery devices market is described by DelveInsight as moderately concentrated, with leading players such as BD (搜索), West Pharmaceutical Services, and Gerresheimer holding significant market shares through broad product portfolios, global distribution networks, and strong regulatory expertise. These companies dominate areas including prefilled syringes, safety devices, autoinjectors, and connected insulin delivery systems.
At the same time, smaller and mid-sized firms—including startups such as Enable Injections, Portal Instruments, and Crossject—are driving niche innovation with wearable injectors, needle-free devices, and AI-enabled smart injectors. Strategic collaborations between pharmaceutical companies and device manufacturers are intensifying competition, while partnerships in digital health integration, sustainability, and patient-centric design are further accelerating product launches and investments in next-generation delivery systems.
Key companies identified across both market analyses include Eli Lilly and Company, Biocon, BD (搜索), West Pharmaceutical Services, Johnson & Johnson Services, AbbVie (搜索), Pfizer, Mylan (now part of Viatris), Gerresheimer AG (搜索), SCHOTT AG, Terumo Corporation, Teva Pharmaceutical Industries, F. Hoffmann-La Roche, Novartis AG, GSK plc, Sanofi, Merck & Co., and Amgen.
Injectable Segment Leads Broader Drug Delivery Market
MarketsandMarkets' analysis of the broader pharmaceutical drug delivery market reinforces the centrality of injectables, with the injectable drug delivery segment expected to hold a significant share by 2031. This growth is driven by the increasing use of biologics, biosimilars, and advanced therapies that require parenteral administration for optimal efficacy. Injectables offer advantages such as rapid onset of action, higher bioavailability, and precise dosing, making them essential for treating conditions such as cancer, diabetes (搜索), and autoimmune diseases.
Technological innovations—including prefilled syringes, autoinjectors, wearable injectors, lipid nanoparticles, and controlled-release formulations—are supporting next-generation therapeutics such as mRNA-based treatments, cell and gene therapies, and high-viscosity biologics by ensuring drug stability, accurate dosing, and improved patient adherence.
However, both reports acknowledge market challenges. MarketsandMarkets notes that the high cost and technical complexity of drug-device combination products, along with stringent regulatory requirements from global authorities including the FDA, EMA, PMDA, NMPA, and CDSCO, are increasing development timelines and compliance burdens for manufacturers.